{"nctId":"NCT04060199","briefTitle":"Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)","startDateStruct":{"date":"2020-04-14","type":"ACTUAL"},"conditions":["Duchenne Muscular Dystrophy"],"count":77,"armGroups":[{"label":"Viltolarsen","type":"EXPERIMENTAL","interventionNames":["Drug: Viltolarsen"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Viltolarsen","otherNames":["NS-065/NCNP-01"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male â‰¥ 4 years and \\< 8 years of age\n* Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon 53 to restore the dystrophin mRNA reading frame\n* Able to walk independently without assistive devices\n* TTSTAND \\< 10 seconds\n* Stable dose of glucocorticoid (GC) for at least 3 months prior to study entry and is expected to remain on stable dose of GC treatment for the duration of the study\n* Other inclusion criteria may apply\n\nExclusion Criteria:\n\n* Current or history of chronic systemic fungal or viral infections\n* Acute illness within 4 weeks prior to the first dose of study drug\n* Evidence of symptomatic cardiomyopathy (Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary)\n* Allergy or hypersensitivity to the study drug or to any of its constituents\n* Severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the investigator\n* Previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the investigator;\n* Surgery within the 3 months prior to the first dose of study drug or surgery is planned for anytime during the duration of the study\n* Participant has positive test results for hepatitis B antigen, hepatitis C antibody or human immunodeficiency virus (HIV)\n* Currently taking any other investigational drug or has taken any other investigational drug within 3 months prior to the first dose of study drug or within 5 times the half-life of a medication, whichever is longer\n* Previously enrolled in an interventional study of viltolarsen\n* Currently taking any other exon skipping agent or has taken any other exon skipping agent within 3 months prior to the first dose of study drug\n* Having taken any gene therapy\n* Other exclusion criteria may apply","healthyVolunteers":false,"sex":"MALE","genderBased":true,"minimumAge":"4 Years","maximumAge":"7 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Time to Stand (TTSTAND) Velocity","description":"The change from baseline for velocity converted from TTSTAND was compared between the viltolarsen-treated patients and the placebo-treated patients. TTSTAND was assessed as the time it takes the participant to go from lying flat on the floor to standing. The time measured for TTSTAND was converted to a velocity expressed as rise per second.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.026","spread":"0.0103"},{"groupId":"OG001","value":"0.013","spread":"0.0104"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.027","spread":"0.0100"},{"groupId":"OG001","value":"0.014","spread":"0.0100"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.027","spread":"0.0107"},{"groupId":"OG001","value":"0.027","spread":"0.0108"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.009","spread":"0.0096"},{"groupId":"OG001","value":"0.013","spread":"0.0096"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":38},"commonTop":["COVID-19","Pyrexia","Upper respiratory tract infection","Cough","Nasopharyngitis"]}}}